

Zealous Therapeutics: Small molecule drug discovery for cancer and inflammation

20 December 2017 | 11 am to 12 pm

Conference room, Venture Center, 900 NCL Innovation Park

Abstract of the talk

Zealous Therapeutics (ZT) is a small molecule drug discovery company registered in Singapore in 2013, with offices in Boston and Hyderabad. The aim of ZT is to develop a cost-effective drug for cancer and inflammatory disorders. We are committed to filling the existing gap between early-stage to pre-IND or phase 1 drug discoveries and then collaborate with big pharma to advance the program. The team has 150-man years of experience with 10 Ph.D. scientists, advisors with a track record of identifying novel drugs. ZT team has used a proprietary algorithm with computational modeling approaches. ZT has synthesized compounds with the help of Chemtracks (India) and tested with Reaction Biology Inc (USA) for 3-5 targets. The selected targets are in the area of epigenetics, inflammation, and immunotherapy such as SIRT1/2, PRMT5, and IRAK4. Founders have self-invested 0.2 million USD for target selection, computational modeling, and ongoing chemical synthesis. ZT is looking for collaborative program for government or private funding for in vivo studies to collaborate with big pharma for advancing drug candidates.

Speaker's profile



Dr. Manish Bais, VMD, PhD (Research Associate Professor at Boston University, Boston; Founder & Director, Zealous Therapeutics Pvt Ltd.)

Dr. Manish Bais, VMD, PhD (Research Associate Professor at Boston University, Boston; Founder & Director, Zealous Therapeutics Pvt Ltd.). My academic research over the last 12+ years has focused on arthritis, genetic and epigenetic regulation of oral cancer and translational research. I am also Founder & Director, Zealous Therapeutics, and collaborated in industry project related to small and large molecule drug discovery.

Organized by



Interested?

Register on email:

bioincubator@venturecenter.co.in